Abstract
The majority of patients with myelodysplastic syndromes (MDS) become transfusion-dependent during the course of disease and may thus develop transfusional iron overload. As a further contributor to iron overload there is increased absorption of dietary iron from the gut, as a consequence of ineffective erythropoiesis. Compared with thalassemia, it is less clear how frequent patients with MDS develop clinical complications of iron overload, and whether the accumulation of iron shortens their survival. This review aims to summarize our current knowledge of the detrimental effects of transfusional iron overload in MDS, point out the risks associated with ironinduced oxidative stress, describe the tools available for diagnosing iron overload, indicate the treatment options with currently available iron chelators, and discuss the measurement of labile plasma iron (LPI) as a tool to monitor the efficacy of iron chelation therapy.
Keywords: Iron overload, myelodysplastic syndromes, oxidative stress, non-transferrin-bound iron, labile plasma iron, iron chelation, dietary iron, transfusional iron overload, erythropoiesis, hemoglobin
Current Pharmaceutical Design
Title:Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Volume: 18 Issue: 22
Author(s): Norbert Gattermann
Affiliation:
Keywords: Iron overload, myelodysplastic syndromes, oxidative stress, non-transferrin-bound iron, labile plasma iron, iron chelation, dietary iron, transfusional iron overload, erythropoiesis, hemoglobin
Abstract: The majority of patients with myelodysplastic syndromes (MDS) become transfusion-dependent during the course of disease and may thus develop transfusional iron overload. As a further contributor to iron overload there is increased absorption of dietary iron from the gut, as a consequence of ineffective erythropoiesis. Compared with thalassemia, it is less clear how frequent patients with MDS develop clinical complications of iron overload, and whether the accumulation of iron shortens their survival. This review aims to summarize our current knowledge of the detrimental effects of transfusional iron overload in MDS, point out the risks associated with ironinduced oxidative stress, describe the tools available for diagnosing iron overload, indicate the treatment options with currently available iron chelators, and discuss the measurement of labile plasma iron (LPI) as a tool to monitor the efficacy of iron chelation therapy.
Export Options
About this article
Cite this article as:
Gattermann Norbert, Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023222
DOI https://dx.doi.org/10.2174/1381612811209023222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
Current Drug Metabolism Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry New Approaches for the Treatment of Chagas Disease
Current Drug Targets Investigation on the Interaction Between Anthracyclines and DNA in the Presence of Quercetin by Resonance Light Scattering Technique and Its Analytical Application
Current Analytical Chemistry Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design NAD+, Sirtuins, and Cardiovascular Disease
Current Pharmaceutical Design Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Perspective on the Role of Four Beta-blockers in Heart Failure
Current Reviews in Clinical and Experimental Pharmacology Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Mitochondrial Injury and Targeted Intervention in Septic Cardiomyopathy
Current Pharmaceutical Design Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry TiO2-Nanowired Delivery of Mesenchymal Stem Cells Thwarts Diabetes- Induced Exacerbation of Brain Pathology in Heat Stroke: An Experimental Study in the Rat Using Morphological and Biochemical Approaches
CNS & Neurological Disorders - Drug Targets Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews